Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

ALN-HTT02

Oligonucleotide (siRNA) · Gene silencing: huntingtin (HTT) · developed by ALNYLAM PHARMACEUTICALS

Phase 1 Most advanced trial

ALNY Developer

1 Registered trials

What is ALN-HTT02?

ALN-HTT02 is an investigational RNA interference agent designed to lower production of huntingtin protein by acting on HTT RNA. It is administered intrathecally and is being studied in Huntington's disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Oligonucleotide (siRNA)
Targets: huntingtin (HTT)
Mechanism: Gene silencing: huntingtin (HTT)
Therapy area: Neurology
Developer: ALNYLAM PHARMACEUTICALS (ALNY)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06585449	Phase 1	Huntington's Disease	Recruiting	ALNY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Huntington's Disease

Other drugs acting on HTT

WVE-003 Phase 1/2 WVE-120101 Phase 1/2 WVE-120102 Phase 1/2

More from ALNYLAM PHARMACEUTICALS

Givosiran FDA approved Lumasiran FDA approved Patisiran FDA approved Vutrisiran FDA approved ALN-2232 Phase 1/2 ALN-4285 Phase 1 ALN-4324 Phase 2 ALN-4915 Phase 1 ALN-5288 Phase 1 ALN-6222 Phase 1 ALN-6400 Phase 1/2 ALN-AGT01 RVR Phase 2

Sources

ClinicalTrials.gov NCT06585449

Updated Oct 11, 2026. Something wrong or missing? Report it on the ALNY page.

Follow ALNY, the company behind ALN-HTT02

See ALNY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ALNY catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z